FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127018518> ?p ?o ?g. }

• W2127018518 endingPage "715" @default.
• W2127018518 startingPage "704" @default.
• W2127018518 abstract "Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) have an unfavourable prognosis with few treatment options. Polatuzumab vedotin is an antibody-drug conjugate containing an anti-CD79B monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the safety and clinical activity of polatuzumab vedotin in relapsed or refractory B-cell NHL and chronic lymphocytic leukaemia (CLL).In this phase 1, multicentre, open-label study, we enrolled patients with documented NHL or CLL expected to express CD79B (confirmation of CD79B expression was not required) and for whom no suitable therapy of curative intent or higher priority existed from 13 centres. The primary endpoints of the study were to assess safety and tolerability, determine the maximum tolerated dose, and identify the recommended phase 2 dose of polatuzumab vedotin as a single agent and in combination with rituximab. A 3 + 3 dose-escalation design was used in which we treated patients with polatuzumab vedotin (0·1-2·4 mg/kg every 21 days) in separate dose-escalation cohorts for NHL and CLL. After determination of the recommended phase 2 dose, we enrolled patients with relapsed or refractory diffuse large B-cell lymphoma and relapsed or refractory indolent NHL into indication-specific cohorts. We also enrolled patients with relapsed or refractory NHL into an additional cohort to assess the feasibility of the combination of polatuzumab vedotin and rituximab 375 mg/m(2). Patients who received any dose of polatuzumab vedotin were available for safety analyses. This study is registered with ClinicalTrials.gov, number NCT01290549.Between March 21, 2011, and Nov 30, 2012, we enrolled 95 patients (34 to the NHL dose-escalation cohort, 18 to the CLL dose-escalation cohort, 34 with NHL to the expansion cohort at the recommended phase 2 dose, and nine with NHL to the rituximab combination cohort; no expansion cohort of CLL was started due to lack of activity in the dose-escalation cohort). The recommended phase 2 dose in NHL was 2·4 mg/kg as a single agent and in combination with rituximab; the maximum tolerated dose in CLL was 1·0 mg/kg as a result of dose-limiting toxic effects reported in two of five patients given 1·8 mg/kg. Grade 3-4 adverse events were reported in 26 (58%) of 45 patients with NHL treated at the single-agent recommended phase 2 dose, and the most common grade 3-4 adverse events were neutropenia (18 [40%] of 45), anaemia (five [11%]), and peripheral sensory neuropathy (four [9%]). Serious adverse events were reported in 17 (38%) of 45 patients, and included diarrhoea (two patients), lung infection (two patients), disease progression (two patients), and lung disorder (two patients). Seven (77%) of nine patients in the rituximab combination cohort had a grade 3-4 adverse event, with neutropenia (five [56%]), anaemia (two [22%]), and febrile neutropenia (two [22%]) reported in more than one patient. 11 (12%) of 95 patients died during the study: eight with relapsed or refractory diffuse large B-cell lymphoma (due to progressive disease in four patients, infections in three patients [two treatment related], and treatment-related worsening ascites in one patient) and three with relapsed or refractory CLL (due to progressive disease, pulmonary infection, and pneumonia; none thought to be treatment-related). At the recommended phase 2 dose, objective responses were noted in 23 of 42 activity-evaluable patients with NHL given single-agent polatuzumab vedotin (14 of 25 with diffuse large B-cell lymphoma, seven of 15 with indolent NHL, and two with mantle-cell lymphoma) and seven of nine patients treated with polatuzumab vedotin combined with rituximab. No objective responses were observed in patients with CLL.Polatuzumab vedotin has an acceptable safety and tolerability profile in patients with NHL but not in those with CLL. Its clinical activity should be further assessed in NHL.Genentech." @default.
• W2127018518 created "2016-06-24" @default.
• W2127018518 creator A5003078312 @default.
• W2127018518 creator A5005718112 @default.
• W2127018518 creator A5009979630 @default.
• W2127018518 creator A5011559739 @default.
• W2127018518 creator A5011946503 @default.
• W2127018518 creator A5020748961 @default.
• W2127018518 creator A5024827460 @default.
• W2127018518 creator A5024988764 @default.
• W2127018518 creator A5025865972 @default.
• W2127018518 creator A5026641386 @default.
• W2127018518 creator A5035562927 @default.
• W2127018518 creator A5043162057 @default.
• W2127018518 creator A5051605599 @default.
• W2127018518 creator A5060314041 @default.
• W2127018518 creator A5062305482 @default.
• W2127018518 creator A5074729432 @default.
• W2127018518 creator A5078791373 @default.
• W2127018518 creator A5083088355 @default.
• W2127018518 creator A5086354986 @default.
• W2127018518 creator A5086858204 @default.
• W2127018518 creator A5089448461 @default.
• W2127018518 date "2015-06-01" @default.
• W2127018518 modified "2023-09-30" @default.
• W2127018518 title "Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study" @default.
• W2127018518 cites W1559459501 @default.
• W2127018518 cites W1885901959 @default.
• W2127018518 cites W2011118089 @default.
• W2127018518 cites W2041498582 @default.
• W2127018518 cites W2050100708 @default.
• W2127018518 cites W2060466778 @default.
• W2127018518 cites W2065528643 @default.
• W2127018518 cites W2084433006 @default.
• W2127018518 cites W2090057677 @default.
• W2127018518 cites W2101893838 @default.
• W2127018518 cites W2126855868 @default.
• W2127018518 cites W2127749132 @default.
• W2127018518 cites W2133201432 @default.
• W2127018518 cites W2134861285 @default.
• W2127018518 cites W2142099365 @default.
• W2127018518 cites W2142195688 @default.
• W2127018518 cites W2143154854 @default.
• W2127018518 cites W2155256323 @default.
• W2127018518 cites W2156506990 @default.
• W2127018518 cites W2172003817 @default.
• W2127018518 doi "https://doi.org/10.1016/s1470-2045(15)70128-2" @default.
• W2127018518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25925619" @default.
• W2127018518 hasPublicationYear "2015" @default.
• W2127018518 type Work @default.
• W2127018518 sameAs 2127018518 @default.
• W2127018518 citedByCount "229" @default.
• W2127018518 countsByYear W21270185182015 @default.
• W2127018518 countsByYear W21270185182016 @default.
• W2127018518 countsByYear W21270185182017 @default.
• W2127018518 countsByYear W21270185182018 @default.
• W2127018518 countsByYear W21270185182019 @default.
• W2127018518 countsByYear W21270185182020 @default.
• W2127018518 countsByYear W21270185182021 @default.
• W2127018518 countsByYear W21270185182022 @default.
• W2127018518 countsByYear W21270185182023 @default.
• W2127018518 crossrefType "journal-article" @default.
• W2127018518 hasAuthorship W2127018518A5003078312 @default.
• W2127018518 hasAuthorship W2127018518A5005718112 @default.
• W2127018518 hasAuthorship W2127018518A5009979630 @default.
• W2127018518 hasAuthorship W2127018518A5011559739 @default.
• W2127018518 hasAuthorship W2127018518A5011946503 @default.
• W2127018518 hasAuthorship W2127018518A5020748961 @default.
• W2127018518 hasAuthorship W2127018518A5024827460 @default.
• W2127018518 hasAuthorship W2127018518A5024988764 @default.
• W2127018518 hasAuthorship W2127018518A5025865972 @default.
• W2127018518 hasAuthorship W2127018518A5026641386 @default.
• W2127018518 hasAuthorship W2127018518A5035562927 @default.
• W2127018518 hasAuthorship W2127018518A5043162057 @default.
• W2127018518 hasAuthorship W2127018518A5051605599 @default.
• W2127018518 hasAuthorship W2127018518A5060314041 @default.
• W2127018518 hasAuthorship W2127018518A5062305482 @default.
• W2127018518 hasAuthorship W2127018518A5074729432 @default.
• W2127018518 hasAuthorship W2127018518A5078791373 @default.
• W2127018518 hasAuthorship W2127018518A5083088355 @default.
• W2127018518 hasAuthorship W2127018518A5086354986 @default.
• W2127018518 hasAuthorship W2127018518A5086858204 @default.
• W2127018518 hasAuthorship W2127018518A5089448461 @default.
• W2127018518 hasConcept C121332964 @default.
• W2127018518 hasConcept C126322002 @default.
• W2127018518 hasConcept C142424586 @default.
• W2127018518 hasConcept C143998085 @default.
• W2127018518 hasConcept C159654299 @default.
• W2127018518 hasConcept C197934379 @default.
• W2127018518 hasConcept C203014093 @default.
• W2127018518 hasConcept C2777325958 @default.
• W2127018518 hasConcept C2778191690 @default.
• W2127018518 hasConcept C2778375690 @default.
• W2127018518 hasConcept C2779338263 @default.
• W2127018518 hasConcept C2780653079 @default.
• W2127018518 hasConcept C2992779791 @default.
• W2127018518 hasConcept C31760486 @default.
• W2127018518 hasConcept C535046627 @default.

• next